Activation of GABA_A receptors in the medial prefrontal cortex produces an anxiolytic-like response

Solati J, Hajikhani R, Golub Y. Activation of GABA_A receptors in the medial prefrontal cortex produces an anxiolytic-like response.

Objectives: There has been increasing evidence that the γ -aminobutyric acid (GABA)ergic system is involved in the neurobiology of anxiety. The present study aimed to investigate the role of GABAergic systems in the modulation of anxiety in the medial prefrontal cortex (mPFC) of rats using the elevated plus maze test.

Methods: Rats were anaesthetised with a mixture of ketamine and xylazine, and then special cannulae were inserted stereotaxically into the mPFC. After 5–7 days of recovery, the effects of intra-mPFC administration of GABAergic agents were studied.

Results: Bilateral injection of the GABA_A receptor agonist muscimol (0.25, 0.5 and 1 μ g/rat) produces an anxiolytic-like effect, shown by significant increases in the percentage of open-arm time (%OAT) and percentage of open-arm entries (%OAE). Intra-mPFC administration of the GABA_A receptor antagonist bicuculline (0.25, 0.5 and 1 μ g/rat) produces significant anxiogenic-like behaviour. However, intra-mPFC injection of the GABA_B receptor agonist baclofen (0.05, 0.1 and 0.2 μ g/rat) and the GABA_B receptor antagonist CGP35348 (5, 10 and 15 μ g/rat) did not alter %OAT and %OAE significantly.

Conclusion: The results of the present study demonstrate that the GABAergic system of the mPFC modulates anxiety-related behaviours of rats through GABA_A receptors.

Jalal Solati¹, Ramin Hajikhani¹, Yulia Golub²

¹Department of Biology, Karaj branch, Islamic Azad University, Karaj, Iran; and ²Department of Child and Adolescent Mental Health, University of Erlangen-Nuremberg

Keywords: anxiety, GABA, medial prefrontal cortex

Jalal Solati, Department of Biology, School of Science, Karaj Branch, Islamic Azad University, Karaj, Iran.

Tel: +98261 4418143;

Fax: +98261 4418156;

E-mail solati@kia.ac.ir;

Accepted for publication September 3, 2012

First published online 8 March, 2013

Significant outcomes

- Anxiety behaviours of animals are controlled by the γ -aminobutyric acid (GABA)ergic system of the medial prefrontal cortex (mPFC).
- GABA_A receptors of the mPFC modulate the effects of GABA on anxiety-related behaviour.

Limitations

- In the present study the role of GABA receptors has been evaluated only in the medial area of the prefrontal cortex. The role of these receptors in other areas of the PFC and possible interaction between these areas need to be evaluated to understand the role of GABAergic neurotransmission in the PFC in anxiety.

Introduction

PFC is a collection of cortical areas in the most anterior portion of the frontal lobes. The anatomical organisation of the PFC could be divided into three major sub-regions including the medial PFC, the

lateral PFC and the ventral PFC (1). Several studies have focussed on understanding the role of different PFC sub-regions in the modulation of emotional behaviours (2,3).

GABA is the main inhibitory neurotransmitter of the brain acting through different receptor sites

called GABA_A, GABA_B and GABA_C (4). GABAergic neurons are one of the most important components prevalent in all areas of the brain and its neurotransmission is vital for brain function (5). Although GABA plays a major role in the modulation of virtually all cognitive and behavioural processes, several basic and clinical studies have particularly

highlighted the role of this neurotransmitter in the central modulation of anxiety and stress responses (6–9).

The GABAergic connection between PFC and other brain structures has been reported in previous studies. The entire PFC is highly innervated by projections from different brain nuclei that are involved in the modulation of anxiety and stress. GABAergic innervation of the PFC has an important role in the modulation of cognitive and emotional behaviours (2). GABA-containing neurons in the rat ventral tegmental area project to the PFC (10). Further, GABAergic projections from the PFC also innervate different brain regions such as the nucleus accumbens (11).

In recent times, several studies have demonstrated that the mPFC has an important role in the modulation of behaviours such as learning, memory and anxiety (2,12,13). However, mechanisms underlying the regulation of behaviours through mPFC and the role of different neural systems are not yet clear.

The present study aimed to examine whether the involvement of GABA_A and GABA_B receptors of the mPFC in the regulation of behaviours is associated with anxiety.

Materials and methods

Animals

The animals used in this study were male Wistar rats obtained from the Pasteur Institute of Iran (Tehran, Iran), weighing 200–250 g at the time of surgery. Animals were housed four per cage in a room under a 12:12 h light/dark cycle (lights on at 07:00 h) and controlled temperature. They had access to food and water *ad libitum* and were allowed to adapt to the laboratory conditions for at least 1 week before surgery. Rats were handled about 5 min each day before the behavioural testing. All experiments were conducted between 12:00 and 18:00 h, and each rat was tested only once. Seven animals were used in each experiment. All efforts were made to minimise animal suffering and reduce the number of animals used.

Stereotaxic surgery and microinjections

To implant the cannula, rats were anaesthetised intraperitoneally with ketamine hydrochloride (50 mg/kg; Alfasan, Woerden, The Netherlands) plus xylazine (4 mg/kg; Alfasan) and placed in a Stoelting

stereotaxic instrument. The stainless steel guide cannulae (21 G) were implanted into the right and left mPFC regions according to the atlas of Paxinos and Watson (14). Stereotaxic coordinates for the mPFC regions were AP: +3.5 mm from the bregma, L: ±0.8 mm from the midline and V: –3.3 mm from the skull surface. The cannulae were fixed to the skull with acrylic dental cement. The animals were allowed to recover from the surgery for a period of 7 days before the experiments. The left and right mPFCs were infused with an internal cannula (27 G) apparatus, terminating 1 mm below the tip of the guides, connected by polyethylene tubing to a 1-μl Hamilton syringe. On each side, 0.5 μl solution was injected (1 μl/rat) for 60 s. The inner cannula was left in place for an additional 60 s to allow adequate diffusion of the solution and to reduce the possibility of reflux. IntramPFC injections were performed 5 min before testing. All subjects were allowed to recover for a period of 5–7 days after the surgery before the start of behavioural procedures (15,16).

Elevated plus maze

The elevated plus maze (EPM) is a plus-shaped wooden apparatus elevated 50 cm above the floor. The EPM consists of a central platform (10 cm × 10 cm), two open arms (50 cm × 10 cm) and two equalised closed arms (50 cm × 10 cm × 50 cm) opposite each other with an open roof. The EPM was placed at the centre of a quiet and dimly lit room. Behavioural data were recorded by a “blind” observer who sat quietly 1 m behind one of the closed arms of the EPM, using a chronometer. Five minutes following their respective drug treatments, rats were placed individually at the centre of the EPM, facing one of the closed arms. The observer measured (1) the time spent in the open arms, (2) the time spent in the closed arms, (3) the number of entries into the open arms and (4) the number of entries into the closed arms during the 5-min test period. Open-arm activity was quantified as the amount of time that the rat spent in the open arms relative to the total amount of time spent in any arm (open/total × 100), and the number of entries into the open arms was quantified relative to the total number of entries into any arm (open/total × 100). The total number of open-arm and closed-arm entries was used as indices of general locomotor activity (17,18).

Drugs

The drugs used in the present study were (8)-baclofen, CGP35348, (+)-bicuculline and muscimol (Sigma Chemical Co., St Louis, MO, USA). Baclofen, CGP35348 and muscimol were dissolved in sterile 0.9% saline; bicuculline was dissolved in one drop

of glacial acetic acid and made up to a volume of 5 ml with sterile 0.9% saline.

Experiment design

Effects of GABA_A receptor agonists and antagonists on anxiety-like behaviours. To evaluate the effects of activation or inhibition of GABA_A receptors in the mPFC on anxiety, three groups of rats were infused with muscimol, a selective GABA_A agonist (0.25, 0.5 and 1 µg/rat), three other groups received bicuculline, a GABA_A antagonist (0.25, 0.5 and 1 µg/rat), and their behaviour was compared with that of the saline control group.

Effects of GABA_B receptor agonists and antagonists on anxiety-like behaviours. Three groups of rats received three different doses of the GABA_B receptor agonist baclofen (0.05, 0.1 and 0.2 µg/rat) and three other groups received the GABA_B receptor antagonist CGP35348 (5, 10 and 15 µg/rat) and their behaviours were compared with that of the saline control group.

Histology assessment

After behavioural tests, 1% methylene-blue solution (1 µl/rat, 0.5 µl/side) was bilaterally injected into the mPFC as a marker of the injection sites. Thereafter, each rat was killed using an overdose of chloroform. Brains were removed after decapitation and fixed in a 10% formalin solution. The brains were sliced and the sites of injection were verified using the atlas of Paxinos and Watson (14). Data from animals with injection sites located outside the mPFC region were not used in the analysis (Fig. 5).

Data analysis

One-way ANOVA was used for comparison of the effects of different doses of drugs and saline (control). In the case of significant differences, the *post hoc* analysis (Tukey) was performed to evaluate the comparisons of specific groups. Differences with $p < 0.05$ between experimental groups at each point were considered statistically significant. The statistical package of SPSS (version 16) was used for statistical analysis, and Microsoft Office Excel 2010 was used for drawing graphs.

Results

Effects of GABA_A receptor agonist and antagonist on anxiety

Figure 1 shows the effect of intra-mPFC injection of muscimol (0.25, 0.5 and 1 µg/rat) in the EPM. One-way

Fig. 1. Effects of bilateral intra-medial prefrontal cortex injection of muscimol as seen in the elevated plus maze test. Rats were treated either with saline (1 µl/rat) or with muscimol (0.25, 0.5 and 1 µg/rat). Each bar represents mean $\pm$ SEM. %Open arm time, %open arm entries or locomotor activity. $n = 7$; * $p < 0.05$ and ** $p < 0.01$.

ANOVA revealed that muscimol (0.25, 0.5 and 1 µg/rat) increased open-arm time (OAT)% [$F(3, 24) = 6.61$, $p < 0.01$] and open-arm entries (OAE)% [$F(3, 24) = 6.16$, $p < 0.01$]. No significant change in locomotor activity was observed [$F(3, 24) = 1.829$, $p > 0.05$], indicating an anxiolytic-like response.

However, rats infused intra-mPFC with bicuculline (0.25, 0.5 and 1 µg/rat) showed significant decrease in OAT% [$F(3, 24) = 5.524$, $p < 0.01$] and OAE% [$F(3, 24) = 5.081$, $p < 0.01$]. No significant change in locomotor activity was observed [$F(3, 24) = 1.231$, $p > 0.05$], indicating an anxiogenic-like response (Fig. 2).

Effects of GABA_B receptor agonist and antagonist on anxiety

One-way ANOVA shows that intra-mPFC injection of GABA_B receptor agonist baclofen (0.05, 0.1 and

Fig. 2. Effects of bilateral intra-medial prefrontal cortex injection of bicuculline as seen in the elevated plus maze test. Rats were treated either with saline (1 μ l/rat) or with bicuculline (0.25, 0.5 and 1 μ g/rat). Each bar represents mean $\pm$ SEM. %Open arm time, %open arm entries or locomotor activity. $n = 7$; * $p < 0.05$ and ** $p < 0.01$.

0.2 μ g/rat) did not alter OAT% [$F(3, 24) = 2.011$, $p > 0.05$], OAE% [$F(3, 24) = 1.199$, $p > 0.05$] and locomotor activity [$F(3, 24) = 1.21$, $p > 0.05$] significantly (Fig. 3).

Intra-mPFC infusion with GABA_B receptor antagonist CGP (5, 10 and 15 μ g/rat) also had no significant effects on OAT% [$F(3, 24) = 2.011$, $p > 0.05$], OAE% [$F(3, 24) = 1.199$, $p > 0.05$] and locomotor activity (Fig. 4).

Discussion

Results of the present study show that intra-mPFC administration of GABA_A receptor agonist muscimol increases OAT% and OAE%, without significant effects on locomotor activity, indicating the reduced anxiety by activation of GABA_A receptors. However,

Fig. 3. Effects of bilateral intra-medial prefrontal cortex injection of baclofen as seen in the elevated plus maze test. Rats were treated either with saline (1 μ l/rat) or with baclofen (0.05, 0.1 and 0.2 μ g/rat). Each bar represents mean $\pm$ SEM. %Open arm time, %open arm entries or locomotor activity; $n = 7$.

intra-mPFC microinjection of bicuculline decreases OAT% and OAE%, indicating the induction of anxiogenic-like response. Activation of the GABA_B receptors of mPFC by baclofen or inhibition of them by CGP has no significant effect on anxiety-related behaviours. Our result demonstrates that the GABAergic system of mPFC modulates anxiety-related behaviours via GABA_A receptors, and activation of GABA_A receptors in this area attenuates anxiety-related behaviours in adult male Wistar rats, whereas inhibition of these receptors by bicuculline produces an anxiogenic profile.

The GABAergic system and GABA receptors are the most important neural systems involved in the modulation and control of anxiety. The important role of GABA_A receptors in the modulation of different forms of anxiety, fear and stress depression has been reported in several studies (19,20). A functional association between the increased GABAergic

Fig. 4. Effects of bilateral intra-medial prefrontal cortex injection of CGP as seen in the elevated plus maze test. Rats were treated either with saline (1 µl/rat) or with bicuculline (5, 10 and 15 µg/rat). Each bar represents mean ± SEM. %Open arm time, %open arm entries or locomotor activity.

neurotransmission and reduced emotional responses such as anxiety and fearfulness following aversive stimulation has been frequently proposed (21,22).

Pharmacological studies showed that GABA_A receptor activation increases chloride conductance and inhibits neuronal activity by hyperpolarisation or depolarisation block and attenuates anxiety- and stress-related behavioural aberrations, whereas antagonists of this receptor usually enhance the behavioural sequelae generated by stressors and administration of these agents could induce behavioural disturbances and physiological changes comparable to those observed in stressed and anxious animals (21,23). Although some studies have reported that bicuculline generally has no specific effects on animal models of anxiety (24,25) and it has been suggested that anxiogenesis observed after bicuculline administration may be attributed to behavioural

Fig. 5. The approximate placements of the injection cannula within the mPFC are indicated by circles. Representative sections of the mPFC were taken from the rat brain atlas of Paxinos and Watson (14).

suppression rather than to any effect on anxiety (24), several studies have shown the anxiogenic effects of bicuculline when injected into different brain areas (9,26,27).

The GABAergic connection between PFC and other brain structures is probably also involved in modulation of anxiety-related behaviours (28,29). Previous studies have reported that GABA-containing neurons in the rat ventral tegmental area project to the PFC and GABAergic projections from PFC also innervate different brain regions such as the nucleus accumbens (11,30). Anxiety disorders may relate to

perturbations in this ventral PFC-amygdala circuit. A study on anxious youth using selective imaging of the amygdala showed that patients showed greater response to threat-related facial expressions and increased amygdala activation and abnormal ventral PFC responses. These neural abnormalities may be responsible for regulatory processes of anxiety-related behaviours (4,31).

Only the role of GABA receptors in the mPFC has been evaluated in the present study. Further studies are required on the role of these receptors in other areas of PFC, as well as on the possible interaction between these areas for a full understanding of the role of GABAergic neurotransmission in the PFC on modulation of anxiety-related behaviour.

Acknowledgement

This work was supported by research deputy of Islamic Azad University-Karaj branch.

References

1. GEORGE O, KOOB GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. *Neurosci Biobeh Rev* 2010;**35**:232–247.
2. YAN Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex. *Mol Neurobiol* 2002;**26**:203–216.
3. JINKS AL, MCGREGOR IS. Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat. *Brain Res* 1997;**772**:181–190.
4. MONK C, NELSON E, MCCLURE E et al. Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. *Amer J Psychiatry* 2006;**163**:1091–1097.
5. TSUTSUI K, UKENA K, USUI M, SAKAMOTO H, TAKASE M. Novel brain function: biosynthesis and actions of neurosteroids in neurons. *Neuroscience Res* 2000;**36**:261–273.
6. HASLER G, VAN DER VEEN JW, GRILLON C, DREVETS WC, SHEN J. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. *Amer J psychiatry* 2010;**167**:1226–1231.
7. SHEKHAR A. GABA receptors in the region of the dorsomedial hypothalamus of rats regulate anxiety in the elevated plus-maze test. I. Behavioral measures. *Brain res* 1993;**627**:9–16.
8. HIRANI K, SHARMA AN, JAIN NS, UGALE RR, CHOPDE CT. Evaluation of GABAergic neuroactive steroid 3 α -hydroxy-5 α -pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. *Psychopharmacology* 2005;**180**:267–278.
9. ZARRINDAST MR, SOLATI J, ORYAN S, PARIVAR K. Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats. *Pharmacology* 2008;**82**:276–284.
10. CARR DB, SESACK SR. GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. *Synapse* 2000;**38**:114–123.
11. TORREGROSSA MM, TANG XC, KALIVAS PW. The glutamatergic projection from the prefrontal cortex to the nucleus accumbens core is required for cocaine-induced decreases in ventral pallidal GABA. *Neurosci Let* 2008;**438**:142–145.
12. SIMPSON J, DREVETS W, SNYDER A, GUSNARD D, RAICHEL M. Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. *Proc Natl Acad Sci USA* 2001;**98**:688–693.
13. LACROIX L, WHITE I, FELDON J. Effect of excitotoxic lesions of rat medial prefrontal cortex on spatial memory. *Behav Brain Res* 2002;**133**:69–81.
14. PAXINOS G, WATSON C. The rat brain in stereotaxic coordinates. Amsterdam: Elsevier, 2007.
15. SOLATI J, SALARI AA, BAKHTIARI A. 5HT 1A and 5HT 1B receptors of medial prefrontal cortex modulate anxiogenic-like behaviors in rats. *Neurosci Let* 2011;**504**:325–329.
16. SOLATI J. Dorsal hippocampal N-methyl-d-aspartate glutamatergic and [delta]-opioidergic systems modulate anxiety behaviors in rats in a noninteractive manner. *Kaohsiung J Med Sci* 2011;**27**:485–493.
17. SOLATI J, ZARRINDAST M, SALARI A. Dorsal hippocampal opioidergic system modulates anxiety-like behaviors in adult male Wistar rats. *Psychiatry Clin Neurosci* 2010;**634**–641.
18. SOLATI J, SALARI A. Involvement of dorsal hippocampal NMDA-glutamatergic system in anxiety-related behaviors of rats. *Neurochemical J* 2011;**5**:194–199.
19. KALUEFF AV, NUTT DJ. Role of GABA in anxiety and depression. *Depress Anxiety* 2007;**24**:495–517.
20. TASAN RO, BUKOVAC A, PETERSCHMITT YN et al. Altered GABA transmission in a mouse model of increased trait anxiety. *Neuroscience* 2011;**183**:71–80.
21. MATSUMOTO M, TOGASHI H, KAKU A, KANNO M, TAHARA K, YOSHIOKA M. Cortical GABAergic regulation of dopaminergic responses to psychological stress in the rat dorsolateral striatum. *Synapse* 2005;**56**:117–121.
22. DEPINO AM, TSETSENIS T, GROSS C. GABA homeostasis contributes to the developmental programming of anxiety-related behavior. *Brain Res* 2008;**1210**:189–199.
23. KALUEFF A, NUTT D. Role of GABA in memory and anxiety. *Depress Anxiety* 1996;**4**:100–110.
24. ÁGMO A, PRUNEDA R, GUZMÁN M, GUTIÉRREZ M. GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. *Naunyn-Schmiedeberg Arch Pharmacol* 1991;**344**:314–322.
25. DALVI A, RODGERS R. GABAergic influences on plus-maze behaviour in mice. *Psychopharmacology* 1996;**128**:380–397.
26. HODGE CW, RABER J, MCMAHON T et al. Decreased anxiety-like behavior, reduced stress hormones, and neurosteroid supersensitivity in mice lacking protein kinase Cepsilon. *J Clin Invest* 2002;**110**:1003–1010.
27. SANDERS S, SHEKHAR A. Regulation of anxiety by GABA_A receptors in the rat amygdala. *Pharmacol Biochem Behav* 1995;**52**:701–706.
28. LEWIS DA. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. *Brain Res Rev* 2000;**31**:270–276.
29. HASHIMOTO T, ARION D, UNGER T et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry* 2007;**13**:147–161.
30. NAIR-ROBERTS R, CHATELAIN-BADIE S, BENSON E, WHITE-COOPER H, BOLAM J, UNGLESS M. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. *Neuroscience* 2008;**152**:1024–1031.
31. MONK CS, TELZER EH, MOGG K et al. Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. *Arch Gen Psychiatry* 2008;**65**:568–576.